1. Home
  2. SINT vs XCUR Comparison

SINT vs XCUR Comparison

Compare SINT & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SiNtx Technologies Inc.

SINT

SiNtx Technologies Inc.

N/A

Current Price

$2.13

Market Cap

10.9M

Sector

Health Care

ML Signal

N/A

Logo Exicure Inc.

XCUR

Exicure Inc.

N/A

Current Price

$1.18

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SINT
XCUR
Founded
1996
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
9.2M
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
SINT
XCUR
Price
$2.13
$1.18
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
★ $9.13
N/A
AVG Volume (30 Days)
★ 29.4K
22.1K
Earning Date
11-12-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
59.45
★ 83.37
EPS
N/A
★ N/A
Revenue
★ $1,018,000.00
N/A
Revenue This Year
$190.28
N/A
Revenue Next Year
$79.38
$44.02
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.40
$1.05
52 Week High
$4.64
$9.48

Technical Indicators

Market Signals
Indicator
SINT
XCUR
Relative Strength Index (RSI) 66.00 40.95
Support Level $1.83 $1.05
Resistance Level $2.46 $1.48
Average True Range (ATR) 0.16 0.09
MACD 0.04 -0.00
Stochastic Oscillator 64.20 21.77

Price Performance

Historical Comparison
SINT
XCUR

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: